A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Clinical trial NCT06101134 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06101134
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-06
- Primary completion
- 2025-04-10
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.